$0.23
▼ -0.2% Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
Theriva Biologics Gets Spain Approval for Phase 2a Trial of Pancreatic Cancer Therapy
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
Overview
52-week range
$0.16
$0.86
10% of range
Avg surprise (last 0)
—
Avg reaction (last 2)
+0.9%
50% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $-0.05 | — | — | +96.8% | 0.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.45 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-1.93 | — | — | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-1.55 | — | — | — | +1.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-6.81 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-10.72 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-7.53 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-4.85 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.34 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | — | -$1.93 |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $300,000 | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-2M | — | $-4M | $-13M | $-4M | — | $-8M | $-8M |
| Net income | — | — | — | — | — | — | — | — |
| EPS (diluted) | $-0.05 | — | $-0.45 | $-1.93 | $-1.55 | — | $-6.81 | $-10.72 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $14M | $13M | $8M | $12M | $10M | $12M | $16M | $17M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $17M | $17M | $10M | $15M | $12M | $16M | $20M | $20M |
| Total assets | $38M | $38M | $31M | $36M | $32M | $35M | $40M | $42M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $23M | $23M | $24M | $25M | $17M | $16M | $15M | $15M |
| Total equity | — | — | — | — | — | — | — | — |
Implied volatility — last 90 days
No IV snapshots yet for TOVX.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.